Niraparib plus abiraterone and prednisone shows mixed results in HRR-mutated mCRPC
New drug combo extends life for some prostate cancer patients
This retrospective cohort study of 5 patients with HRR-mutated metastatic castration-resistant prostate cancer evaluated niraparib plus abir…
Some men with advanced prostate cancer are living longer with a powerful new drug combo, even when they’re older or too weak for harsh treat…
Phase 2 trial of pembrolizumab and DNA vaccines in metastatic prostate cancer shows no significant difference
Prostate Cancer Vaccine Strategy Shows Tumor Responses, But One Arm Adds Risk
This early Phase 2 trial evaluated pembrolizumab combined with pTVG-HP or pTVG-AR DNA vaccines in 60 patients with metastatic castration-res…
A two-vaccine strategy did not improve survival over a single vaccine in advanced prostate cancer, yet both approaches shrank tumors in some…
Meta-analysis associates emerging lesions after lutetium-177 therapy with worse overall survival in mCRPC
Emerging lesions on scans linked to lower survival in prostate cancer patients
This systematic review and meta-analysis evaluated interim post-treatment SPECT/CT findings in 648 patients with metastatic castration-resis…
New spots appearing on scans after treatment for advanced prostate cancer are linked to significantly lower survival rates.
Systematic review of PSMA-directed CAR-T therapy for mCRPC highlights barriers and emerging platforms
New immune cell therapies show promise for advanced prostate cancer
This systematic review examines PSMA-directed CAR-T cell therapy for metastatic castration-resistant prostate cancer. Durable clinical respo…
Engineered immune cells offer new hope for hard-to-treat prostate cancer, but durable responses remain rare.
Talazoparib plus enzalutamide shows high probability of benefit in Japanese mCRPC subgroup
New Math Brings Hope to Japanese Men With Advanced Prostate Cancer
A Bayesian reanalysis of phase III trial data in 116 Japanese patients with metastatic castration-resistant prostate cancer found a 98% prob…
New math suggests a two-drug combo likely works for Japanese men with advanced prostate cancer, even when original trial numbers looked unce…
Deutenzalutamide improves rPFS in mCRPC after abiraterone and docetaxel progression.
New Pill Slows Advanced Prostate Cancer After Other Drugs Fail
A randomized phase III trial in 417 patients with metastatic castration-resistant prostate cancer after progression on or intolerance to abi…
A new daily pill slowed advanced prostate cancer progression by 42 percent in men whose disease grew despite standard hormone therapy and ch…
Olaparib plus durvalumab showed activity in mCRPC patients previously treated with abiraterone or enzalutamide.
Two Cancer Drugs Teamed Up — Who Actually Benefits Most?
This single-arm, open-label phase 2 trial evaluated olaparib plus durvalumab in 60 men with metastatic castration-resistant prostate cancer …
A new prostate cancer drug combo helped men with specific DNA repair gene variants live more than twice as long without their cancer progres…
FDA Approves Pluvicto (lutetium Lu 177 vipivotide tetraxetan) for PSMA-positive metastatic castration-resistant prostate cancer.
FDA approves a new treatment for advanced prostate cancer called Pluvicto.
The FDA has approved Pluvicto, a radioligand therapeutic agent, for the treatment of adult patients with PSMA-positive metastatic castration…
FDA approves Pluvicto, a targeted radiation therapy for advanced prostate cancer that has spread and stopped responding to standard hormone …
Lu-PSMA-617 plus pembrolizumab shows PSA response in mCRPC phase 1b/2 trial
Can a new drug combo help men with advanced prostate cancer?
In a single-arm phase 1b/2 trial of 37 patients with mCRPC, Lu-PSMA-617 plus pembrolizumab achieved a 50% PSA decline in 28 participants (76…
A new drug combo helped 28 of 37 men with advanced prostate cancer cut their PSA levels in half while keeping side effects mostly mild to mo…
Phase II study of 177Lu-PSMA-617 in mCRPC shows 50% PSA response and median OS of 18.8 months
Can a targeted radiation treatment help men with advanced prostate cancer?
A prospective, single-arm phase II study of 48 PSMA-avid mCRPC patients treated with 177Lu-PSMA-617 found a 50% PSA response rate and median…
A targeted radiation therapy helped half of men with advanced prostate cancer lower their cancer markers and kept nearly 88% alive after one…
Meta-analysis finds 47% PSA decline >50% with Ac-225/Lu-177 PSMA combination in mCRPC
Can a new two-drug radiation combo help men with advanced prostate cancer?
A meta-analysis of 323 patients with mCRPC found that Ac-225/Lu-177 PSMA radioligand combination therapy was associated with a pooled PSA de…
A new two-drug radiation combo helped 78% of men with advanced prostate cancer lower their PSA levels, with nearly half seeing a substantial…